{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006543","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.475937+00:00","generated_at":"2026-06-03T00:36:24.283568+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NextCure posts Q1 net loss of $17.1M; cash $96M; NC410 data at ASCO June 1","bullets":["Cash $96.0M as of March 31, 2024, down $12.3M from Q4 2023; expected to fund operations into H2 2026.","Net loss of $17.1M for Q1 2024 vs $16.1M in Q1 2023; R&D $11.4M, G&A $4.4M, restructuring costs $2.5M.","Phase 1b NC410 combo with pembrolizumab data at ASCO June 1, including additional 20 CRC patients.","LNCB74 (B7-H4 ADC) advancing; IND submission planned by year-end with GLP tox studies initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006543","json":"https://secwatch.observer/filing/0001558370-24-006543.json","markdown":"https://secwatch.observer/filing/0001558370-24-006543.md","text":"https://secwatch.observer/filing/0001558370-24-006543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/0001558370-24-006543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/nxtc-20240502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:36:24.283568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65fd9f7969472740c0f63e7e96340fa8c900854d","claim":"NextCure, Inc. reported first quarter 2024 results: net income Net loss was $17.1 million.","evidence_excerpt":"NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/0001558370-24-006543-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"Net loss was $17.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}